JUNS Stock Analysis: Buy, Sell, or Hold?
JUNS - Jupiter Neurosciences, Inc. Common Stock
$0.10
0.01 (10.89%)
▲
5d:
-12.07%
30d:
-55.25%
90d:
-74.41%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 17, 2026
13d
Get Alerted When JUNS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: JUNS is down 12.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: JUNS is down 12.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: JUNS is currently trading at $0.10, which is considered oversold relative to its 30-day fair value range of $0.13 to $0.22. From a valuation perspective, the stock is trading at a discount (Forward PE: 1.5) compared to its historical average (8.7). Remarkably, the market is currently pricing in an annual earnings decline of 44.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, JUNS is in a strong downtrend. Immediate support is located at $0.08, while resistance sits at $0.24. The stock is showing strong short-term momentum, up 10.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $30.00 (+33233.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, JUNS is in a strong downtrend. Immediate support is located at $0.08, while resistance sits at $0.24. The stock is showing strong short-term momentum, up 10.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $30.00 (+33233.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.13 -
$0.22
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+10.9%)
- BULLISH: Trading 33233.3% below Wall St target ($30.00)
- WARNING: Recommendation downgraded due to -12.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.13 -
$0.22
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.08
Resistance Level
$0.24
Current Trend
Strong Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.50
Wall Street Target
$30.00
(+33233.3%)
Valuation Discount vs History
-44.3% cheaper
PE vs Historical
1.5 vs 8.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-44.3%
(market-implied from PE analysis)
1-Year Target
$0.08
(-10%)
2-Year Target
$0.07
(-19%)
3-Year Target
$0.07
(-27%)
3-Yr Target (if PE normalizes)
(PE: 2→9)
$0.38
(+323%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 1.5 to 8.7
Stabilization Target:
$0.52
(+480.0%)
PE Expansion Potential:
+480.0%
Share & Embed Analysis
Last updated: August 03, 2026 1:56 PM ET
Data refreshes hourly during market hours. Next update: 2:56 PM
Data refreshes hourly during market hours. Next update: 2:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JUNS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 51 HOLD |
